Sign up today and save up to 67% on a Hartford Courant digital subscription


Report: Drug maker was focused on profits, not patients

The makers of a breakthrough hepatitis drug put profits before patients in pricing the $1,000 pill that's become a symbol of the excessive cost of medications, Senate investigators said Tuesday.

A bipartisan report from the Senate Finance Committee concluded that California-based Gilead Sciences Inc. was focused on maximizing revenue for its hepatitis C medications, even as the company's own analysis showed a lower price would allow more patients to be treated.

The lawmakers who led the investigation said it's a warning about what could happen with other innovative treatments for cancer, diabetes, Alzheimer's and HIV.

"I'm telling you, this is the future,"...